U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C34H67O10P
Molecular Weight 666.8635
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL-

SMILES

CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC

InChI

InChIKey=BPHQZTVXXXJVHI-UHFFFAOYSA-N
InChI=1S/C34H67O10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-33(37)41-29-32(30-43-45(39,40)42-28-31(36)27-35)44-34(38)26-24-22-20-18-16-14-12-10-8-6-4-2/h31-32,35-36H,3-30H2,1-2H3,(H,39,40)

HIDE SMILES / InChI

Molecular Formula C34H67O10P
Molecular Weight 666.8635
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL- is a component of ABELCET® (Amphotericin B Lipid Complex Injection). It consists of amphotericin B complexed with two phospholipids in a 1:1 drug-to-lipid molar ratio. The two phospholipids, l-α-dimyristoylphosphatidylcholine and l-α-dimyristoylphosphatidylglycerol, are present in a 7:3 molar ratio. ABELCET® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. This is based on the open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin B therapy.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ABELCET

Approved Use

ABELCET® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy.

Launch Date

1.28735995E12

Sample Use Guides

The recommended daily dosage for adults and children is 5 mg/kg given as a single infusion. ABELCET® should be administered by intravenous infusion at a rate of 2.5 mg/kg/h. If the infusion time exceeds 2 hours, mix the contents by shaking the infusion bag every 2 hours.
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:48:31 UTC 2023
Edited
by admin
on Fri Dec 15 17:48:31 UTC 2023
Record UNII
BI71WT9P3R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL-
Common Name English
ALFQ component DMPG
Common Name English
1,2-DIMYRISTOYL-GLYCERO-3-PHOSPHO-(1'-RAC-GLYCEROL)
Common Name English
14:0 PG
Common Name English
Army Liposome Formulation component DMPG
Common Name English
ALF component DMPG
Common Name English
DMPG, DL-
Common Name English
DMPG
Common Name English
1,2-DIMYRISTOYL-GLYCERO-3-(PHOSPHO-RAC-(1-GLYCEROL))
Common Name English
DMPG, (±)-
Common Name English
DIMYRISTOYLPHOSPHATIDYLGLYCEROL
Common Name English
TETRADECANOIC ACID, 1,1'-(1-((((2,3-DIHYDROXYPROPOXY)HYDROXYPHOSPHINYL)OXY)METHYL)-1,2-ETHANEDIYL) ESTER
Common Name English
Code System Code Type Description
CHEBI
60723
Created by admin on Fri Dec 15 17:48:31 UTC 2023 , Edited by admin on Fri Dec 15 17:48:31 UTC 2023
PRIMARY
DRUG CENTRAL
4650
Created by admin on Fri Dec 15 17:48:31 UTC 2023 , Edited by admin on Fri Dec 15 17:48:31 UTC 2023
PRIMARY
RXCUI
1427047
Created by admin on Fri Dec 15 17:48:31 UTC 2023 , Edited by admin on Fri Dec 15 17:48:31 UTC 2023
PRIMARY
EVMPD
SUB22206
Created by admin on Fri Dec 15 17:48:31 UTC 2023 , Edited by admin on Fri Dec 15 17:48:31 UTC 2023
PRIMARY
EPA CompTox
DTXSID80976890
Created by admin on Fri Dec 15 17:48:31 UTC 2023 , Edited by admin on Fri Dec 15 17:48:31 UTC 2023
PRIMARY
RXCUI
1427048
Created by admin on Fri Dec 15 17:48:31 UTC 2023 , Edited by admin on Fri Dec 15 17:48:31 UTC 2023
ALTERNATIVE
CAS
61361-72-6
Created by admin on Fri Dec 15 17:48:31 UTC 2023 , Edited by admin on Fri Dec 15 17:48:31 UTC 2023
PRIMARY
DRUG BANK
DB11284
Created by admin on Fri Dec 15 17:48:31 UTC 2023 , Edited by admin on Fri Dec 15 17:48:31 UTC 2023
PRIMARY
DAILYMED
BI71WT9P3R
Created by admin on Fri Dec 15 17:48:31 UTC 2023 , Edited by admin on Fri Dec 15 17:48:31 UTC 2023
PRIMARY
FDA UNII
BI71WT9P3R
Created by admin on Fri Dec 15 17:48:31 UTC 2023 , Edited by admin on Fri Dec 15 17:48:31 UTC 2023
PRIMARY
PUBCHEM
107767
Created by admin on Fri Dec 15 17:48:31 UTC 2023 , Edited by admin on Fri Dec 15 17:48:31 UTC 2023
PRIMARY
MESH
C002773
Created by admin on Fri Dec 15 17:48:31 UTC 2023 , Edited by admin on Fri Dec 15 17:48:31 UTC 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY